Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma

Abstract Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adul...

Full description

Saved in:
Bibliographic Details
Main Authors: Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Biomarker Research
Subjects:
CAR-T
CD19
Chimeric antigen receptor T-cell
R/R DLBCL
Real-world study
Tafasitamab
Online Access:https://doi.org/10.1186/s40364-024-00706-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40364-024-00706-6

Similar Items